{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:42:15Z","timestamp":1789879335797,"version":"4.0.1"},"reference-count":72,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2007,3,9]],"date-time":"2007-03-09T00:00:00Z","timestamp":1173398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,3,9]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Persistent infection with oncogenic human papillomavirus (HPV) is a necessary cause of cervical cancer. Moreover, HPV type 16 (and to a lesser degree HPV type 18) is linked with more rare cancers, namely cancer of the vulva, vagina, penis, anus, oropharynx and larynx. Effective prophylactic vaccines have been developed. In this review, we briefly address immunological aspects of HPV infection and the results of HPV vaccination trials. Internationally standardized monitoring and evaluation of prophylactic HPV vaccination programmes will be essential for arriving at the most (cost-)effective strategies for cancer control.<\/jats:p>","DOI":"10.1111\/j.1365-2249.2007.03384.x","type":"journal-article","created":{"date-parts":[[2008,10,15]],"date-time":"2008-10-15T12:36:33Z","timestamp":1224074193000},"page":"199-207","source":"Crossref","is-referenced-by-count":42,"title":["Translational Mini-Review Series on Vaccines:&amp;#x2028;Monitoring of human papillomavirus vaccination"],"prefix":"10.1093","volume":"148","author":[{"given":"J","family":"Dillner","sequence":"first","affiliation":[{"name":"WHO Global Reference Laboratory for HPV Diagnosis and Control, Department of Clinical Microbiology, University Hospital, SE-20502 Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Arbyn","sequence":"additional","affiliation":[{"name":"Scientific Institute of Public Health, Brussels, Belgium and European Cancer Network, IARC, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Dillner","sequence":"additional","affiliation":[{"name":"WHO Global Reference Laboratory for HPV Diagnosis and Control, Department of Clinical Microbiology, University Hospital, SE-20502 Malm\u00f6, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,4,8]]},"reference":[{"key":"2022010414520492800_b1","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/infdis\/174.5.927","article-title":"The natural history of human papillomavirus type 16 capsid antibodies among a cohort of University women","volume":"174","author":"Carter","year":"1996","journal-title":"J Infect Dis"},{"key":"2022010414520492800_b2","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1086\/315498","article-title":"Comparison of human papillomavirus types 16, 18 and 6 capsid antibody responses following incident infection","volume":"181","author":"Carter","year":"2000","journal-title":"J Infect Dis"},{"key":"2022010414520492800_b3","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1158\/1055-9965.EPI-03-0191","article-title":"Natural history of human papillomavirus type 16 virus-like particle antibodies in young women","volume":"13","author":"Ho","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2022010414520492800_b4","first-page":"233","article-title":"Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix","volume":"6","author":"Shah","year":"1997","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2022010414520492800_b5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1386-6532(01)00172-X","article-title":"Human Papillomavirus infection, risk for subsequent development of cervical neoplasia and associated population attributable fraction","volume":"22","author":"Lehtinen","year":"2001","journal-title":"J Clin Virol"},{"key":"2022010414520492800_b6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1006\/scbi.1999.0146","article-title":"The serological response to papillomaviruses","volume":"9","author":"Dillner","year":"1999","journal-title":"Semin Cancer Biol"},{"issue":"17","key":"2022010414520492800_b7","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/jnci\/89.17.1293","article-title":"Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer","volume":"89","author":"Dillner","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"2022010414520492800_b8","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/infdis\/173.6.1394","article-title":"Seropositivity to human papillomavirus types 16 1996, 18 or 33 capsids and to Chlamydia trachomatis are markers of sexual behaviour","volume":"173","author":"Dillner","journal-title":"J Infect Dis"},{"key":"2022010414520492800_b9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0738-081X(85)90047-1","article-title":"Human papillomaviruses. Biochemical and biologic properties","volume":"3","author":"Orth","year":"1985","journal-title":"Clin Dermatol"},{"key":"2022010414520492800_b10","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1128\/jvi.70.5.3298-3301.1996","article-title":"Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition","volume":"70","author":"Roden","year":"1996","journal-title":"J Virol"},{"key":"2022010414520492800_b11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1006\/gyno.1994.1239","article-title":"Role of conformational epitopes expressed by human papillomavirus major capsid proteins in the serologic detection of infection and prophylactic vaccination","volume":"55","author":"Hines","year":"1994","journal-title":"Gynecol Oncol"},{"key":"2022010414520492800_b12","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/0042-6822(91)90890-N","article-title":"The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes","volume":"181","author":"Christensen","year":"1991","journal-title":"Virology"},{"key":"2022010414520492800_b13","doi-asserted-by":"crossref","first-page":"6188","DOI":"10.1128\/JVI.73.7.6188-6190.1999","article-title":"Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6","volume":"73","author":"Kawana","year":"1999","journal-title":"J Virol"},{"key":"2022010414520492800_b14","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1006\/viro.2000.0272","article-title":"Minor capsid protein of human genital papillomaviruses contains subdominant, crossneutralizing epitopes","volume":"270","author":"Roden","year":"2000","journal-title":"Virology"},{"key":"2022010414520492800_b15","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1128\/JVI.73.6.4882-4889.1999","article-title":"Characterization of a major neutralizing epitope on human papillomavirus type 16, L1","volume":"73","author":"White","year":"1999","journal-title":"J Virol"},{"key":"2022010414520492800_b16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/(SICI)1097-4644(19990501)73:2<145::AID-JCB1>3.0.CO;2-5","article-title":"Chimeric papillomavirus virus-like particles induce a murine self-antigen-specifik protective and therapeutic antitumor immune response","volume":"73","author":"Nieland","year":"1999","journal-title":"J Cell Biochem"},{"key":"2022010414520492800_b17","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1073\/pnas.95.4.1800","article-title":"Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model","volume":"95","author":"Greenstone","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022010414520492800_b18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0042-6822(91)90772-4","article-title":"Expression of vaccinia recombinant HPV16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles","volume":"185","author":"Zhou","year":"1991","journal-title":"Virology"},{"key":"2022010414520492800_b19","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/jnci\/86.7.494","article-title":"A virus-like particle ELISA detects serum antibodies in a majority of women infected with human papillomavirus type 16","volume":"86","author":"Kirnbauer","year":"1994","journal-title":"J Natl Cancer Inst"},{"key":"2022010414520492800_b20","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1099\/0022-1317-78-9-2209","article-title":"A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera","volume":"78","author":"Wang","year":"1997","journal-title":"J General Virol"},{"key":"2022010414520492800_b21","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1006\/viro.2001.1220","article-title":"Hybrid papillomavairus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types","volume":"291","author":"Christensen","year":"2001","journal-title":"Virology"},{"key":"2022010414520492800_b22","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1099\/vir.0.82449-0","article-title":"Deletion of a major neutralizing epitope of Human Papillomavirus type 16 virus-like particles","volume":"88","author":"Ryding","year":"2007","journal-title":"J General Virol"},{"key":"2022010414520492800_b23","first-page":"1","article-title":"Human cellular immune responses against human papillomaviruses in cervical neoplasia","author":"Man","year":"1998","journal-title":"Expert Rev Mol Medical 1998"},{"key":"2022010414520492800_b24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.tim.2003.12.011","article-title":"Dendritic cells: the host Achille's heel for mucosal pathogensarticle-title","volume":"12","author":"Niedergang","year":"2004","journal-title":"Trends Microbiol"},{"key":"2022010414520492800_b25","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1517\/13543784.13.8.959","article-title":"Recent developments in human papillomavirus vaccines","volume":"13","author":"Stern","year":"2004","journal-title":"Expert Opin Invest Drugs"},{"key":"2022010414520492800_b26","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4\u20135 years of bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"key":"2022010414520492800_b27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.AOG.0000192397.41191.fb","article-title":"Efficacy of Human Papillomavirus 16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial","volume":"107","author":"Mao","year":"2006","journal-title":"Obstet Gynecol"},{"key":"2022010414520492800_b28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prohylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncol"},{"key":"2022010414520492800_b29","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"key":"2022010414520492800_b30","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa020586","article-title":"A controlled trial of human papillomavirus type 16 vaccine","volume":"347","author":"Koutsky","year":"2002","journal-title":"N Engl J Med"},{"key":"2022010414520492800_b31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcv.2006.12.009","article-title":"Review of current knowledge on HPV vaccination: An appendix to the European Guidelines for Quality Assurance in cervical cancer screening","volume":"38","author":"Arbyn","year":"2007","journal-title":"J Clin Virol"},{"key":"2022010414520492800_b32","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1126\/science.308.5722.618","article-title":"Public health. High hopes and dilemmas for a cervical cancer vaccine","volume":"308","author":"Cohen","year":"2005","journal-title":"Science"},{"key":"2022010414520492800_b33","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jcv.2004.11.019","article-title":"HPV-mediated transformation of the anogenital tract","volume":"32","author":"Steenbergen","year":"2005","journal-title":"J Clin Virol"},{"key":"2022010414520492800_b34","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc798","article-title":"Papillomaviruses and cancer: from basic studies to clinical application","volume":"2","author":"Zur Hausen","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"2022010414520492800_b35","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.jcv.2004.12.005","article-title":"Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination","volume":"32","author":"Stern","year":"2005","journal-title":"J Clin Virol"},{"key":"2022010414520492800_b36","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.vaccine.2006.05.123","article-title":"Chapter 17: Second generation HPV vaccines to prevent cervical cancer","volume":"24","author":"Schiller","year":"2006","journal-title":"Vaccine"},{"key":"2022010414520492800_b37","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1586\/14760584.2.3.381","article-title":"Progress in prophylactic and therapeutic vaccines for human papillomavirus infection","volume":"2","author":"Stanley","year":"2003","journal-title":"Expert Rev Vaccines"},{"key":"2022010414520492800_b38","first-page":"35","article-title":"Chapter 4: Burden and management of non-cancerous HPV-related conditions","volume":"24","author":"Lacey","year":"2006","journal-title":"HPV-6\/11 Dis Vaccine"},{"key":"2022010414520492800_b39","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S1470-2045(05)70086-3","article-title":"Carcinogenicity of human papillomaviruses","volume":"6","author":"Cogliano","year":"2005","journal-title":"Lancet Oncol"},{"key":"2022010414520492800_b40","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.vaccine.2004.07.046","article-title":"Efficacy and other milestones for human papillomavirus vaccine introduction","volume":"23","author":"Pagliusi","year":"2004","journal-title":"Vaccine"},{"key":"2022010414520492800_b41","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/oxfordjournals.jncimonographs.a003472","article-title":"Chapter 16: Prophylactic human papillomavirus vaccines","volume":"31","author":"Lowy","year":"2003","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2022010414520492800_b42","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","article-title":"Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16 and 18","volume":"24","author":"Villa","year":"2006","journal-title":"Vaccine"},{"key":"2022010414520492800_b43","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/aje\/kwf180","article-title":"Genital human papillomavirus infection: incidence and risk factors in a cohort of female University students","volume":"157","author":"Winer","year":"2003","journal-title":"J Epidemiol"},{"key":"2022010414520492800_b44","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/S0140-6736(00)04956-4","article-title":"Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study","volume":"357","author":"Woodman","year":"2001","journal-title":"Lancet"},{"key":"2022010414520492800_b45","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199210293271804","article-title":"A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection","volume":"327","author":"Koutsky","year":"1992","journal-title":"N Engl J Med"},{"key":"2022010414520492800_b46","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/sj.bjc.6603575","article-title":"Strategies for the introduction of HPV vaccination: modelling the optimum age and sex specific pattern of vaccination in Finland","volume":"96","author":"French","year":"2007","journal-title":"Br J Cancer"},{"key":"2022010414520492800_b47","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1086\/425271","article-title":"Role of herd immunity in determining the effect of vaccines against sexually transmitted disease","volume":"19","author":"Garnett","year":"2005","journal-title":"J Infect Dis"},{"key":"2022010414520492800_b48","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3201\/eid1011.040222","article-title":"Evaluating human papillomavirus vaccination programs","volume":"10","author":"Taira","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"2022010414520492800_b49","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/00001648-200211000-00006","article-title":"The theoretical population-level impact of a prophylactic human papilloma virus vaccine","volume":"13","author":"Hughes","year":"2002","journal-title":"Epidemiol"},{"key":"2022010414520492800_b50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.0030138","article-title":"Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: Mathematical modelling analyses","volume":"3","author":"Barnabas","year":"2006","journal-title":"Plos Med"},{"key":"2022010414520492800_b51","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.vaccine.2006.05.116","article-title":"Chapter 21. Modelling the impact of HPV vaccines on cervical cancer and screening programmes","volume":"24","author":"Garnett","year":"2006","journal-title":"Vaccine"},{"key":"2022010414520492800_b52","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1258\/095646206776253453","article-title":"Population-based enrolment of adolescents in a long-term follow-up trial of human papillomavirus vaccine efficacy","volume":"17","author":"Lehtinen","year":"2006","journal-title":"Int J STD AIDS"},{"key":"2022010414520492800_b53","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1258\/095646206778145550","article-title":"Enrolment of 22\u2003000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing","volume":"17","author":"Lehtinen","year":"2006","journal-title":"Int J STD AIDS"},{"key":"2022010414520492800_b54","first-page":"1","article-title":"Preparations for implementing human papillomavirus vaccination should begin","volume":"10","author":"Lehtinen","year":"2005","journal-title":"Euro Surveill"},{"key":"2022010414520492800_b55","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/S0140-6736(04)17410-2","article-title":"Vaccination against human papillomaviruses shows great promise","volume":"364","author":"Lehtinen","year":"2004","journal-title":"Lancet"},{"key":"2022010414520492800_b56","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Munoz","year":"2003","journal-title":"N Engl J Med"},{"key":"2022010414520492800_b57","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ijc.20244","article-title":"Against which human papillomavirus types shall we vaccinate and screen? The international perspective","volume":"111","author":"Munoz","year":"2004","journal-title":"Int J Cancer"},{"key":"2022010414520492800_b58","volume-title":"International Agency for Research on Cancer (IARC) Cancerbase No. 5","author":"Ferlay","year":"2004"},{"key":"2022010414520492800_b59","doi-asserted-by":"publisher","volume-title":"Burden of cervical cancer in Europe: estimates for 2004","author":"Arbyn","DOI":"10.1093\/annonc\/mdm079"},{"key":"2022010414520492800_b60","doi-asserted-by":"crossref","first-page":"6571","DOI":"10.1073\/pnas.94.12.6571","article-title":"Vaccination against colonizing bacteria with multiple serotypes","volume":"94","author":"Lipsitch","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"2022010414520492800_b61","first-page":"953","article-title":"Correlates of the spread of human papillomavirus infection","volume":"9","author":"Silins","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2022010414520492800_b62","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/00007435-200307000-00010","article-title":"Occurrence of cervical infection with multiple human papillomavirus types is associated with age and cytologic abnormalities","volume":"30","author":"Rousseau","year":"2003","journal-title":"Sex Transm Infect"},{"key":"2022010414520492800_b63","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1086\/444391","article-title":"Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines","volume":"192","author":"Mendez","year":"2005","journal-title":"J Infect Dis"},{"key":"2022010414520492800_b64","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ijc.20970","article-title":"Chlamydia trachomatis infection and persistence of Human Papillomavirus","volume":"116","author":"Silins","year":"2005","journal-title":"Int J Cancer"},{"key":"2022010414520492800_b65","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1006\/viro.2000.0702","article-title":"HPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16","volume":"279","author":"Pastrana","year":"2001","journal-title":"Virology"},{"key":"2022010414520492800_b66","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.vaccine.2006.05.026","article-title":"Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases","volume":"24","author":"Clifford","year":"2006","journal-title":"Vaccine"},{"issue":"Supplement_3","key":"2022010414520492800_b67","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.vaccine.2006.05.117","article-title":"Chapter 9. Clinical applications of HPV testing: a summary of meta-analyses","volume":"24","author":"Arbyn","year":"2006","journal-title":"Vaccine"},{"key":"2022010414520492800_b68","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.vaccine.2006.05.111","article-title":"Chapter 2. The burden of HPV-related cancers","volume":"24","author":"Parkin","year":"2006","journal-title":"Vaccine"},{"key":"2022010414520492800_b69","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/01.AOG.0000120143.50098.c7","article-title":"Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more","volume":"103","author":"Goldie","year":"2004","journal-title":"Obstet Gynecol"},{"key":"2022010414520492800_b70","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrmicro867","article-title":"Delivering on the promise: HPV vaccines and cervical cancer","volume":"2","author":"Schiller","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"2022010414520492800_b71","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/ijc.21515","article-title":"Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses","volume":"118","author":"Ferguson","year":"2006","journal-title":"Int J Cancer"},{"key":"2022010414520492800_b72","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1128\/JCM.44.2.571-579.2006","article-title":"Results of the first World Health Organization international collaborative study of detection of human papillomavirus DNA","volume":"44","author":"Quint","year":"2006","journal-title":"J Clin Microbiol"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2007.03384.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/148\/2\/199\/42054456\/j.1365-2249.2007.03384.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/148\/2\/199\/42054456\/j.1365-2249.2007.03384.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T15:02:00Z","timestamp":1641308520000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/148\/2\/199\/6457763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,9]]},"references-count":72,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2007,4,8]]},"published-print":{"date-parts":[[2007,3,9]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.2007.03384.x","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,5]]},"published":{"date-parts":[[2007,3,9]]}}}